Scientists Share Data about Malignant Hyperthermia

	Tweet

Travel Award Available to share data with Clinicians and Scientists to advance the diagnosis, treatment, and management of Malignant Hyperthermia-Susceptible Patients April 23-24, 2010 at Mercy Hospital University of Pittsburgh Medical Center.

There is no charge for medical and graduate students, or residents to attend the MHAUS Sponsored Scientific Conference: “Malignant Hyperthermia: New Insights and Connections with Other Myopathies.”

Session Topics and Speakers are: “Pathophysiology of MH - Overview and Recent Advances in Understanding” presented by Chair: Jerome Parness, MD, PhD, UPMC; “Genetics of MH: Results and Future Directions” presented by Chair: Sheila Muldoon, MD, Uniformed Services University of the Health Sciences (USUHS); “MH Epidemiology and Case Studies & Future Directions/ Challenges” presented by Chair: Henry Rosenberg, MD, CPE, Saint, Barnabas Medical Center.

Full meeting agenda is available and MHAUS anticipates receiving 14 or more CME credits for this program.

Poster Presentations - Deadline for submission is March 15, 2010; see website for details.

Submission of abstracts for poster presentation by researchers and clinicians with an active interest in MH and related disorders is encouraged. A travel award to support the cost of conference attendance will be offered to the investigator who submits the highest quality abstract.

Malignant Hyperthermia is reaction to commonly used volatile gaseous anesthesia which can result in death in minutes, unless the patient receives rapid emergency therapy from medical professionals trained to recognize and treat MH quickly.

A patient’s response to anesthesia includes: a rise in heart rate, greatly increased body metabolism, muscle rigidity and/or fever that may exceed 110 degree Fahrenheit; complications can include cardiac arrest, brain damage, internal bleeding and other body system failure. Without emergency therapy for MH, the patient has a greater than 85% chance of death.

MH is an autosomal dominant genetic disorder, so if your mother or father has it, you have a 50:50 chance of inheriting it.

MH tragedies have devastated families, medical professionals’ careers, and medical facilities alike, but it does not have to --- MH emergencies are manageable 95% of the time.

The mission of MHAUS is to promote optimum care and scientific understanding of MH and related disorders.

Malignant Hyperthermia Association of the United States

RELATED STORIES:
Alcohol and Cancer: Know Your Limit   Study reveals inaccuracies in studies of cancer treatment   Black Raspberries May Slow Growth of Colon, Other Cancers   Low vitamin D tied to cancer risk in men   Obese women less likely to be screened for cancer   Cancer cells accelerate aging and inflammation in the body to drive tumor growth   Cancer-causing gene discovery suggests new therapies   Discovery Could Bring New Metastatic Cancer Treatments   Amgen, Abgenix antibody curbs colon cancer   Scientists decode secrets of a very common virus that can cause cancer   Cancer death rates continue drop: report   Study reveals differences in cancer stage presentation between rural and urban patients   Potent Inhibitor Blocks Tumors from Metastasizing   Drug Therapy to Bolster Immune System Cells Found Effective Toward Childhood Cancer   Cancer society challenges Americans to get active   Researchers find environmentally friendly ways to produce more Taxol   Cancer Research Highlights   Breastfeeding – added protection for cancer survivors?   Personalized medicine helps cancer patients survive   Cancer risks of eating red and processed meat   Killing Cancer Like a Vampire Slayer   Green Tea Blocks Benefits Of Cancer Drug

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]